Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Dompe Farmaceutici
Deal Size : Undisclosed
Deal Type : Agreement
Details : Dompé farmaceutici and FarmaMondo have inked Managed Access Program distribution agreement appointing the FarmaMondo as the exclusive partner to make Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis in Russia and other ...
Brand Name : Oxervate
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 26, 2020
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Dompe Farmaceutici
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Dompe Farmaceutici
Deal Size : Undisclosed
Deal Type : Partnership
Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®
Details : The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikista...
Brand Name : Oxervate
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Dompe Farmaceutici
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?